DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
about
Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like CellsStudy of DNA-ellipticine interaction by capillary electrophoresis with laser-induced fluorescence detection.DNA and histone deacetylases as targets for neuroblastoma treatment.Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2.Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.Ellipticine cytotoxicity to cancer cell lines - a comparative studyOld drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.Natural products and their role in cancer therapy.Biomedical importance of indoles.The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cellsInduced expression of microsomal cytochrome b 5 determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I).NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1.Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.
P2860
Q28547244-55C5563D-6A57-4AEC-A06F-9DA7D2A5E9A0Q34317934-CF31B038-2C3F-4F59-B363-4C03990B14B9Q34320121-5D462746-AE9D-4883-AA22-3C5FDF5B42BAQ34359635-7E67031E-DF75-44E3-8C99-B7D8C960CF98Q34984928-94CB42E0-1181-417B-8B00-3C10FC546D57Q35016427-1A407623-E8CD-4396-A1C3-6F80906AF8FFQ35092039-88CC5323-84F7-4004-99EB-E6A097D55515Q36620686-852A7EA2-7F30-4AC4-BC44-10A0A44F6810Q37736333-C1230CFD-CF91-4EA5-B0B0-795BE2FA1649Q38112598-EEAD638E-5879-41B4-8791-01E8017858BDQ39945769-3BFDA162-0DAE-4CE0-8595-42A2E30AFD17Q40062409-8C36EE52-390D-4FA0-BAB4-37922153322EQ40062483-57C538A2-D08A-449E-8409-AAE854871CADQ44457504-73DF2980-2C52-4996-92A2-F26569F46146
P2860
DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@en
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@nl
type
label
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@en
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@nl
prefLabel
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@en
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@nl
P2093
P2860
P356
P1476
DNA adduct formation by the an ...... etermined by 32P postlabeling.
@en
P2093
Andrea Breuer
Dagmar Aimová
Manfred Wiessler
Martina Stiborová-Rupertová
P2860
P304
P356
10.1002/IJC.11511
P577
2003-12-01T00:00:00Z